Q&A
Q&A Board
Approval System Active
All submissions undergo an administrative review. Only approved inquiries will be publicly visible. Replies are strictly provided by YNK Consulting administrators.
All submissions undergo an administrative review. Only approved inquiries will be publicly visible. Replies are strictly provided by YNK Consulting administrators.
| No | Type | Title | Author | Date | Status |
|---|---|---|---|---|---|
| 10 | Clinical | Inquiry about Clinical Strategy Consulting Timeline | Emily R. | 2026-03-15 | Answered |
| 9 | CMC | Requesting details on formulation development | J. Smith | 2026-03-14 | Waiting |
| 8 | Nonclinical | PK simulation and dose level justification service | M*** P. | 2026-03-12 | Answered |
| 7 | Regulatory | IND Submission Requirements | David K. | 2026-03-10 | Waiting |
| 6 | Clinical | CRO Selection Criteria | Alice B. | 2026-03-08 | Answered |
| 5 | CMC | Cell Line Establishment | P*** T. | 2026-03-05 | Answered |
| 4 | Other | General capability inquiry | Kim S. | 2026-03-01 | Answered |
| 3 | Regulatory | Gap Analysis Timeline | L*** K. | 2026-02-25 | Answered |
| 2 | Clinical | Insourced cPM models | John D. | 2026-02-20 | Answered |
| 1 | Nonclinical | Toxicity study protocol review | Sam Y. | 2026-02-15 | Answered |